RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
5.54
+0.02 (0.27%)
May 13, 2026, 10:16 AM EDT - Market open

Company Description

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States.

It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.

The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery.

RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017.

The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

RxSight, Inc.
RxSight logo
CountryUnited States
Founded1997
IPO DateJul 30, 2021
IndustryMedical Devices
SectorHealthcare
Employees461
CEORonald Kurtz

Contact Details

Address:
100 Columbia
Aliso Viejo, California 92656
United States
Phone949 521 7830
Websiterxsight.com

Stock Details

Ticker SymbolRXST
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$16.00
CIK Code1111485
CUSIP Number78349D107
ISIN NumberUS78349D1072
Employer ID94-3268801
SIC Code3851

Key Executives

NamePosition
Dr. Ronald M. Kurtz M.D.President, Chief Executive Officer and Director
Dr. Ilya Goldshleger Ph.D.Chief Operating Officer
Eric J. WeinbergChief Business Development Officer
Maureen O'ConnellExecutive Vice President of Clinical and Regulatory Affairs
Patrick CullenExecutive Vice President of Quality and Infrastructure Operations
Adam DasheExecutive Vice President of International

Latest SEC Filings

DateTypeTitle
May 6, 202610-QQuarterly Report
May 6, 20268-KCurrent Report
Apr 28, 2026ARSFiling
Apr 28, 2026DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 28, 2026DEF 14AOther definitive proxy statements
Mar 27, 2026SCHEDULE 13G/AFiling
Mar 19, 20268-K/A[Amend] Current report
Feb 26, 2026EFFECTNotice of Effectiveness
Feb 25, 2026POS AMPost-Effective amendments for registration statement
Feb 25, 2026S-8Securities to be offered to employees in employee benefit plans